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Purpose: Dabigatran is a reversible direct thrombin inhibitor, which interacts with the active site in the catalytic domain of the thrombin molecule. 
This thorough QT study assessed electrophysiological effects of single doses of 150 mg and 600 mg dabigatran etexilate in healthy subjects.
Methods:  This study was a randomized, placebo-controlled, blinded, 4-period cross-over study, including an open-label positive control 
(moxifloxacin 400 mg).
ECG profiles using 12-lead 10-s ECGs were recorded during the baseline day and following the randomised study treatment in each period. The time-
matched change from baseline (TMCB) of the individually heart rate corrected QT interval (QTcI) was the primary parameter.
Results:  20 male and 20 female Caucasian subjects (mean age 39 years) entered and completed the study, all treatments were well tolerated.
The mean values of the placebo-adjusted TMCB of QTcI for dabigatran were close to zero at all time points, and all 90% confidence intervals were 
between -5 ms and 5 ms (Fig 1), well below the ICH E14 non-inferiority margin of 10 ms.
Assays sensitivity was shown by placebo-adjusted TMCB of QTcI of more than 10 ms at all timepoints between 1 and 6 hours following moxifloxacin. 
The gMean Cmax of 88 ng/mL (150 mg) and 383 ng/mL (600 mg) in this QT study is considered to provide adequate exposure for the assessment 
of potential effects of dabigatran on the QT interval.
Conclusion: Supratherapeutic plasma levels of dabigatran etexilate do not prolong QTc intervals of the ECG.
